BIM Cancer Research Results

BIM, BIM protein (BCL-2 Interacting Mediator of cell death): Click to Expand ⟱
Source:
Type:
A pro-apoptotic protein that plays a crucial role in regulating cell death, particularly in the context of cancer. BIM is a member of the BCL-2 family of proteins, which are key regulators of apoptosis (programmed cell death).
BIM cancer is characterized by the overexpression of the BIM protein, which is a pro-apoptotic protein that promotes cell death.
BIM protein has been shown to have both tumor-suppressive and tumor-promoting roles, depending on the context.
High BIM expression: Melanoma, lung, breast, colorectal.
Low BIM expression: Leukemia, Lymphoma, Prostate
The expression of BIM can serve as a prognostic marker in several cancers. Higher levels of BIM are often associated with increased apoptosis and better treatment responses, while lower levels may indicate resistance to therapy and poorer outcomes.
Scientific Papers found: Click to Expand⟱
266- ALA,    Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death
- in-vitro, Ovarian, IGROV1
Mcl-1↓, Bcl-xL↓, BIM↑, ROS↑,
1537- Api,    Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer
- Review, PC, NA
TumCP↓, TumCCA↑, Apoptosis↑, MMPs↓, Akt↓, *BioAv↑, *BioAv↓, Half-Life∅, Hif1a↓, GLUT1↓, VEGF↓, ChemoSen↑, ROS↑, Bcl-2↓, Bcl-xL↓, BAX↑, BIM↑,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, eff↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
3156- Ash,    Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug
- Review, Var, NA
MAPK↑, p38↑, BAX↑, BIM↑, CHOP↑, ROS↑, DR5↑, Apoptosis↑, Ferroptosis↑, GPx4↓, BioAv↝, HSP90↓, RET↓, E6↓, E7↓, Akt↓, cMET↓, Glycolysis↓, TCA↓, NOTCH1↓, STAT3↓, AP-1↓, PI3K↓, eIF2α↓, HO-1↑, TumCCA↑, CDK1↓, *hepatoP↑, *GSH↑, *NRF2↑, Wnt↓, EMT↓, uPA↓, CSCs↓, Nanog↓, SOX2↓, CD44↓, lactateProd↓, Iron↑, NF-kB↓,
5449- ATV,    Pleiotropic effects of statins: A focus on cancer
- NA, Var, NA
lipid-P↓, TumCG↓, Apoptosis↑, ChemoSen↑, RAS↓, HMG-CoA↓, HMGCR↓, LDL↓, toxicity↓, Risk↓, P21↑, HDAC↓, Bcl-2↓, BAX↑, BIM↑, Casp↑, cl‑PARP↑, MMP↓, ROS↑, angioG↓, TumMeta↓, PTEN↑, eff↑, OS↑, Remission↑,
1517- CAP,    Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1)
- in-vitro, Bladder, TSGH8301 - in-vitro, CRC, T24/HTB-9
ENOX2↓, TumCCA↑, ERK↓, p‑FAK↓, p‑pax↓, TumCMig↓, EMT↓, SIRT1↓, Dose∅, ROS↑, MMP↓, Bcl-2↓, Bak↑, cl‑PARP↑, Casp3↑, SIRT1↓, ac‑P53↑, BIM↑, p‑RB1↓, cycD1/CCND1↓, Dose∅, β-catenin/ZEB1↓, N-cadherin↓, E-cadherin↑,
4826- CUR,    The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management
- Review, Var, NA
*antiOx↑, *Inflam↑, *ROS↓, Apoptosis↑, TumCP↓, BioAv↓, Half-Life↓, eff↑, TumCCA↑, BAX↑, Bak↑, PUMA↑, BIM↑, NOXA↑, TRAIL↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, cMyc↓, Casp↑, NF-kB↓, STAT3↓, AP-1↓, angioG↓, TumMeta↑, VEGF↓, MMPs↓, DNMTs↓, HDAC↓, ROS↑,
462- CUR,    Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress
- in-vitro, Pca, PC3
Bcl-2↓, MMP↓, cl‑Casp3↑, BAX↑, BIM↑, p‑PARP↑, PUMA↑, p‑P53↑, ROS↑, p‑ERK↑, p‑eIF2α↑, CHOP↑, ATF4↑,
1860- dietFMD,  Chemo,    Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
- in-vitro, BC, SUM159 - in-vitro, BC, 4T1
PI3K↑, Akt↑, mTOR↑, CDK4↑, CDK6↑, hyperG↓, TumCG↓, TumVol↓, Casp3↑, BG↓, eff↑, eff∅, PKA↓, KLF5↓, p‑GSK‐3β↑, Nanog↓, OCT4↓, KLF2↓, eff↑, ROS↑, BIM↑, ASK1↑, PI3K↑, Akt↑, mTOR↑, CDK1↓, CDK4↑, CDK6↑, eff↑,
2849- FIS,    Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells
- in-vitro, Melanoma, U266
TumCD↑, TumCCA↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, p‑Akt↓, p‑mTOR↓, ROS↑, eff↓,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycA1/CCNA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
2832- FIS,    Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
- Review, Var, NA
MMP↓, mtDam↑, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, Bak↑, BIM↑, Bcl-xL↓, Bcl-2↓, P53↑, ROS↑, AMPK↑, Casp9↑, Casp3↑, BID↑, AIF↑, Akt↓, mTOR↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, TumMeta↓, uPA↓, E-cadherin↑, Vim↓, EMT↓, Twist↓, DNAdam↑, ROS↓, COX2↓, PGE2↓, HSF1↓, cFos↓, cJun↓, AP-1↓, Mcl-1↓, NF-kB↓, IRE1↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MMP2↓, MMP9↓, TCF-4↓, MMP7↓, RadioS↑, TOP1↓, TOP2↓,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
87- QC,    Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ROS⇅, BAX↑, PUMA⇅, β-catenin/ZEB1↓, Shc↓, TAp63α↑, MAPK↑, p‑p42↑, p‑p44↑, BIM↑,
3061- RES,    The Anticancer Effects of Resveratrol: Modulation of Transcription Factors
- Review, Var, NA
AhR↓, NRF2↑, *NQO1↑, *HO-1↑, *GSH↑, P53↑, Cyt‑c↑, Diablo↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, FOXO↑, p‑PI3K↓, p‑Akt↓, BIM↑, DR4↑, DR5↑, p27↑, cycD1/CCND1↓, SIRT1↑, NF-kB↓, ATF3↑,
4501- SeNPs,    Mechanisms of the Cytotoxic Effect of Selenium Nanoparticles in Different Human Cancer Cell Lines
- in-vitro, GBM, A172 - in-vitro, Colon, Caco-2 - in-vitro, Pca, DU145 - in-vitro, BC, MCF7 - in-vitro, Nor, L929
*BioAv↑, selectivity↑, AntiCan↑, Apoptosis↑, CHOP↑, GADD34↑, BIM↑, PUMA↑, Ca+2↝,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
1002- SSE,  Osi,  Adag,    Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
- in-vitro, Lung, H1975 - in-vitro, Lung, H385
Apoptosis↑, Ferroptosis↑, DNMT1↓, TET1↑, TumCCA↑, cl‑PARP↑, cl‑Casp3↑, Cyt‑c↑, BIM↑, NOXA↑, Apoptosis↑, ROS↑, ER Stress↑, UPR↑,

Showing Research Papers: 1 to 19 of 19

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 19

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ATF3↑, 1,   ENOX2↓, 1,   Ferroptosis↑, 2,   GPx4↓, 1,   GSH↓, 1,   GSTs↓, 1,   HO-1↑, 3,   hyperG↓, 1,   Iron↑, 1,   lipid-P↓, 1,   MDA↑, 1,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 2,   ROS↓, 1,   ROS↑, 15,   ROS⇅, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,   TrxR↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

KLF5↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 2,   CDC2↓, 1,   CDC25↓, 1,   EGF↓, 1,   MEK↓, 2,   MMP↓, 8,   mtDam↑, 1,   p‑p42↑, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↑, 3,   AMPK↑, 3,   cMyc↓, 2,   Glycolysis↓, 2,   HK2↓, 1,   HMG-CoA↓, 1,   lactateProd↓, 1,   LDL↓, 1,   SIRT1↓, 2,   SIRT1↑, 1,   TCA↓, 1,  

Cell Death(tgid=5) ⓘ

AhR↓, 1,   Akt↓, 7,   Akt↑, 2,   p‑Akt↓, 2,   Apoptosis↑, 9,   ASK1↑, 1,   BAD↑, 3,   Bak↑, 4,   BAX↑, 12,   Bcl-2↓, 13,   Bcl-xL↓, 6,   BID↑, 1,   BIM↑, 19,   Casp↑, 3,   Casp3↑, 9,   cl‑Casp3↑, 2,   Casp7↑, 1,   Casp8↑, 2,   cl‑Casp8↑, 1,   Casp9↑, 3,   Cyt‑c↑, 6,   Diablo↑, 4,   DR4↑, 2,   DR5↑, 4,   Fas↑, 1,   Ferroptosis↑, 2,   GADD34↑, 1,   MAPK↓, 1,   MAPK↑, 2,   Mcl-1↓, 6,   MDM2↓, 1,   MLKL↑, 1,   p‑MLKL↓, 1,   Myc↓, 1,   Necroptosis↑, 1,   NOXA↑, 3,   p27↑, 2,   p38↓, 1,   p38↑, 1,   PUMA↑, 3,   PUMA⇅, 1,   survivin↓, 3,   TRAIL↑, 2,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑HER2/EBBR2↓, 1,   RET↓, 1,   Sp1/3/4↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 3,   Shc↓, 1,   tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 5,   eIF2α↓, 1,   p‑eIF2α↑, 2,   ER Stress↑, 2,   GRP78/BiP↑, 1,   HSF1↓, 1,   HSP27↓, 1,   HSP70/HSPA5↓, 2,   HSP90↓, 1,   IRE1↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3B↑, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 4,   DNMT1↓, 1,   DNMTs↓, 1,   P53↑, 4,   p‑P53↑, 2,   ac‑P53↑, 1,   p‑PARP↑, 2,   cl‑PARP↑, 6,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 3,   CDK2↓, 4,   CDK4↓, 4,   CDK4↑, 2,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 6,   cycE/CCNE↓, 1,   P21↑, 4,   RB1↓, 1,   p‑RB1↓, 1,   Securin↓, 1,   TAp63α↑, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 1,   cFos↓, 4,   cMET↓, 2,   CSCs↓, 1,   EMT↓, 5,   ERK↓, 3,   p‑ERK↓, 1,   p‑ERK↑, 1,   FOXO↑, 1,   FOXO3↑, 1,   p‑FOXO3↓, 1,   p‑GSK‐3β↑, 1,   HDAC↓, 2,   HMGCR↓, 1,   mTOR↓, 4,   mTOR↑, 2,   p‑mTOR↓, 1,   Nanog↓, 3,   NOTCH1↓, 1,   OCT4↓, 2,   PI3K↓, 3,   PI3K↑, 2,   p‑PI3K↓, 1,   PTEN↑, 1,   RAS↓, 1,   SOX2↓, 2,   STAT3↓, 3,   TCF↑, 1,   TCF-4↓, 1,   TOP1↓, 1,   TOP2↓, 2,   TumCG↓, 4,   TumCG↑, 1,   Wnt↓, 4,  

Migration(tgid=13) ⓘ

AP-1↓, 3,   Ca+2↝, 1,   E-cadherin↓, 1,   E-cadherin↑, 4,   p‑FAK↓, 1,   Fibronectin↓, 2,   Ki-67↓, 1,   KLF2↓, 1,   MET↓, 1,   MMP1↓, 1,   MMP2↓, 3,   MMP3↓, 1,   MMP7↓, 2,   MMP9↓, 3,   MMPs↓, 2,   N-cadherin↓, 4,   p‑p44↑, 1,   p‑pax↓, 1,   PKA↓, 1,   RIP3↑, 1,   p‑RIP3↑, 1,   Slug↓, 1,   Snail↓, 3,   TET1↑, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 4,   TumMeta↓, 4,   TumMeta↑, 1,   Twist↓, 3,   uPA↓, 4,   Vim↓, 4,   Zeb1↓, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 5,   ATF4↓, 1,   ATF4↑, 3,   EGFR↓, 3,   eNOS↓, 1,   Hif1a↓, 1,   VEGF↓, 3,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 3,   IKKα↓, 1,   IL6↓, 1,   IL8↓, 1,   JAK1↓, 1,   JAK2↓, 1,   NF-kB↓, 8,   NF-kB↑, 1,   p65↓, 1,   PGE2↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 2,   CDK6↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↝, 1,   ChemoSen↑, 5,   Dose∅, 3,   eff↓, 3,   eff↑, 10,   eff∅, 1,   Half-Life↓, 1,   Half-Life∅, 1,   RadioS↑, 2,   selectivity↓, 1,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

BG↓, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 3,   p‑HER2/EBBR2↓, 1,   IL6↓, 1,   Ki-67↓, 1,   Myc↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   cardioP↑, 1,   OS↑, 1,   Remission↑, 1,   Risk↓, 1,   toxicity↓, 2,   TumVol↓, 1,   TumW↓, 2,  
Total Targets: 245

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   GSH↑, 3,   HO-1↑, 1,   lipid-P↓, 1,   NQO1↑, 1,   NRF2↑, 2,   ROS↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,  

Functional Outcomes(tgid=23) ⓘ

hepatoP↑, 2,   neuroP↑, 1,  
Total Targets: 12

Scientific Paper Hit Count for: BIM, BIM protein (BCL-2 Interacting Mediator of cell death)
4 Fisetin
2 Apigenin (mainly Parsley)
2 Curcumin
1 Alpha-Lipoic-Acid
1 Metformin
1 Ashwagandha(Withaferin A)
1 Atorvastatin
1 Capsaicin
1 diet FMD Fasting Mimicking Diet
1 Chemotherapy
1 Piperlongumine
1 Quercetin
1 Resveratrol
1 Selenium NanoParticles
1 Sulforaphane (mainly Broccoli)
1 Selenite (Sodium)
1 Osimertinib
1 Adagrasib
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:483  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page